Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.48 |
| ▸ | SCD | O00767 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3410381 | 0.91 | SMARCA2 (0.42) | SMARCA2SMARCA4SCDSTING1FGFR3 | |
| SCHEMBL3416288 | 0.82 | MET (0.49) | FYNGRK5LRRK2CHEK1KDR | |
| SCHEMBL13209251 | 0.80 | MAPT (0.46) | SMARCA2SMARCA4SCDMAPTMAPK1 | |
| SCHEMBL19370344 | 0.79 | STING1 (0.43) | SMARCA2SMARCA4SCDMAPTMAPK1 | |
| SCHEMBL509162 | 0.79 | FGFR3 (0.47) | SMARCA2SMARCA4SCDMAPTMAPK1 | |
| SCHEMBL29520095 | 0.79 | FGFR3 (0.47) | SMARCA2SMARCA4SCDMAPTMAPK1 | |
| SCHEMBL509607 | 0.78 | SCD (0.42) | SMARCA2SMARCA4SCDMAPTMAPK1 | |
| SCHEMBL24921987 | 0.77 | MAPT (0.50) | SMARCA2SMARCA4SCDMAPTMAPK1 | |
| SCHEMBL13209294 | 0.76 | FYN (0.50) | SMARCA2SMARCA4SCDMAPTMAPK1 | |
| SCHEMBL12940560 | 0.76 | SCD (0.40) | SMARCA2SMARCA4SCDMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016087586-A1 | A DEUTERATED TRIAZOLOPYRIDAZINE AS A KINASE MODULATOR | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-09 | — | — | WO | disclosed |
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8629144-B2 | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-14 | — | — | US | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | SMARCA2 2517/4885SMARCA4 2469/4885SCD 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.